United Services Automobile Association Sells 494 Shares of DexCom, Inc. (NASDAQ:DXCM)

United Services Automobile Association reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.4% in the 2nd quarter, Holdings Channel.com reports. The fund owned 10,847 shares of the medical device company’s stock after selling 494 shares during the period. United Services Automobile Association’s holdings in DexCom were worth $1,230,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Prudential PLC grew its stake in shares of DexCom by 38.6% during the 2nd quarter. Prudential PLC now owns 13,545 shares of the medical device company’s stock worth $1,536,000 after acquiring an additional 3,769 shares in the last quarter. Quest Partners LLC grew its stake in shares of DexCom by 473.8% during the 2nd quarter. Quest Partners LLC now owns 4,298 shares of the medical device company’s stock worth $487,000 after acquiring an additional 3,549 shares in the last quarter. Caprock Group LLC grew its stake in shares of DexCom by 38.1% during the 2nd quarter. Caprock Group LLC now owns 8,595 shares of the medical device company’s stock worth $975,000 after acquiring an additional 2,370 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of DexCom by 206.4% in the second quarter. Acadian Asset Management LLC now owns 24,539 shares of the medical device company’s stock valued at $2,778,000 after buying an additional 16,531 shares in the last quarter. Finally, Stonebrook Private Inc. grew its stake in shares of DexCom by 97.7% in the second quarter. Stonebrook Private Inc. now owns 4,402 shares of the medical device company’s stock valued at $499,000 after buying an additional 2,175 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the transaction, the executive vice president now owns 66,249 shares of the company’s stock, valued at $4,607,617.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the sale, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the sale, the director now owns 25,349 shares in the company, valued at $2,878,378.95. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,311 shares of company stock valued at $234,214. 0.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Oppenheimer decreased their target price on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, July 26th. JPMorgan Chase & Co. cut shares of DexCom from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $145.00 to $75.00 in a research report on Friday, July 26th. Robert W. Baird lifted their price objective on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, August 5th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Finally, UBS Group dropped their target price on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $112.25.

DexCom Stock Up 1.6 %

DXCM stock opened at $69.71 on Tuesday. The company has a market cap of $27.93 billion, a PE ratio of 44.97, a price-to-earnings-growth ratio of 2.12 and a beta of 1.18. The business has a 50-day simple moving average of $85.81 and a 200 day simple moving average of $112.55. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. DexCom’s revenue for the quarter was up 15.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.34 earnings per share. Sell-side analysts anticipate that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.